{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:13:29Z","timestamp":1794564809367,"version":"4.9.1"},"reference-count":16,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T00:00:00Z","timestamp":1360108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate the effect of onabotulinumtoxinA on urodynamic outcomes in patients with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Results from two pivotal Phase III trials (n\u2009=\u2009691) were pooled. MS or SCI patients with NDO, received intradetrusor onabotulinumtoxinA 200\u2009U (n\u2009=\u2009227), 300\u2009U (n\u2009=\u2009223), or placebo (n\u2009=\u2009241). Change from baseline in UI episodes\/week (Week 6), maximum cystometric capacity (MCC), maximum detrusor pressure at first involuntary detrusor contraction (IDC) (P<jats:sub>detmaxIDC<\/jats:sub>), volume at first IDC (V<jats:sub>pmaxIDC<\/jats:sub>), and detrusor compliance (DC) were measured.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>OnabotulinumtoxinA significantly increased MCC overall (+153.6\u2009ml with 200\u2009U vs. +11.9\u2009ml with placebo). Over 60% of onabotulinumtoxinA\u2010treated patients had no IDC at Week 6; in patients with an IDC at Week 6, V<jats:sub>pmaxIDC<\/jats:sub> improved (+183.4\u2009ml with 200\u2009U vs. +17.5\u2009ml with placebo), and P<jats:sub>detmaxIDC<\/jats:sub> decreased (\u221232.4\u2009cmH<jats:sub>2<\/jats:sub>O with 200\u2009U vs. +1.1\u2009cmH<jats:sub>2<\/jats:sub>O with placebo). OnabotulinumtoxinA\u2010treated patients had a significant increase in DC (+59.8\u2009ml\/cmH<jats:sub>2<\/jats:sub>O with 200\u2009U vs. \u22125.2 with placebo). Urodynamic improvements were comparable in patients regardless of baseline DC and corresponded with significant reductions in UI episodes\/week for both onabotulinumtoxinA doses versus placebo, with no clinically relevant differences between 200 and 300\u2009U groups. Most common adverse event was urinary tract infection (UTI); complicated UTIs were low across all treatment groups. In patients not catheterizing at baseline, a dose\u2010dependent increase in post\u2010void residual urine was observed at Week 2 following onabotulinumtoxinA treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>OnabotulinumtoxinA significantly improved urodynamic outcomes in NDO patients, even in those with low baseline DC, and corresponded with improvements in UI episodes. Both doses of onabotulinumtoxinA were well tolerated. <jats:italic>Neurourol. Urodynam. 32:1109\u20131115, 2013<\/jats:italic>. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.22376","type":"journal-article","created":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T13:13:44Z","timestamp":1360156424000},"page":"1109-1115","source":"Crossref","is-referenced-by-count":65,"title":["Onabotulinumtoxin<scp>A<\/scp> improves urodynamic outcomes in patients with neurogenic detrusor overactivity"],"prefix":"10.1002","volume":"32","author":[{"given":"Eric","family":"Rovner","sequence":"first","affiliation":[{"name":"Department of Urology Medical University of South Carolina Charleston South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Dmochowski","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[{"name":"Royal Hallamshire Hospital Sheffield United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thompson","sequence":"additional","affiliation":[{"name":"Allergan, Ltd. Marlow United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Lam","sequence":"additional","affiliation":[{"name":"Allergan, Inc. Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Haag\u2010Molkenteller","sequence":"additional","affiliation":[{"name":"Allergan, Inc. Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.phm.0000219229.92056.c2"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2401"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_7_6_1","first-page":"317","volume-title":"Incontinence","author":"Homma Y","year":"2002"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.1998.11719505"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/01952307.1993.11735878"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67730-0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2011.110"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67283-7"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.12.004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.08.048"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.08.039"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36136-0"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00114-0"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)30277-9"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22376","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.22376","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T01:21:27Z","timestamp":1696382487000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,6]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/nau.22376"],"URL":"https:\/\/doi.org\/10.1002\/nau.22376","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,6]]}}}